en_USEnglish zh_CNChinese

Search the whole station

Home Page Top

  • 恒赛生物DC疫苗治疗EBV相关血液肿瘤项目落地海南乐...

    Hengsai Biological DC Vaccine for EBV-related Hematological Tumors Project Landed in Ruijin Hospital of Lecheng, Hainan Province

    115

    On December 30, 2025, Hengsai Bio's premiere pipeline KSD-101 dendritic cell (DC) vaccine for the treatment of EBV-related hematological tumors, a project of translational application of new biomedical technologies, was officially landed in the Hainan Hospital of Ruijin Hospital, Affiliated to the Medical College of Shanghai Jiao Tong University. The project has been declared and selected, evaluated by experts, verified at the production site and approved by the Health Commission of Hainan Province, the Administration of Lecheng Advance Zone and the Drug Administration jointly. ...

    View details
  • 恒赛生物完成首轮战略融资

    Hengsai Biologicals Closes First Round of Strategic Financing

    106

    Recently, Hengsai Biologics completed the first round of strategic financing, exclusively invested by Tianshili Capital. This round of funding will be mainly used to promote the R&D and clinical trials of the core pipeline as well as the company's internationalization strategy layout. Both parties have carried out extensive and in-depth communication and planning on domestic and international project cooperation. In the future, they will give full play to their respective business advantages, with equity investment as the core link, through business synergy,...

    View details
  • EXPANDED ACCESS TO INVESTIGATIONAL DRUGS POLICY

    authorized access to international regulations and policies

    120

    1. PURPOSE This document describes KOUSAI´s position, and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. This document describes KOUSAI´s position and reflects our Corporate Policy on how patients in medical need may be able to access our new medicines before they are fully approved for use on prescription. 2. SCOPE We cover ...

    View details
  • 恒创前沿・赛领健康 | 恒赛生物临港研发生产基地启...

    Hengchuang Frontier・Sai Leads Health | Grand Opening Ceremony of Hengsai Bio-Linkport R&D and Production Base

    585

    On August 15, 2025, the opening ceremony of the R&D and production base of Hengsai Biologicals in Lingang was held grandly in the 10th phase of Life Blue Bay Intelligence Park in Lingang New Area. With the theme of "Hengchuang Frontier, Sai Leads Health", the ceremony invited the Lingang Administrative Committee, industry experts, shareholders' representatives, partners, leaders of the park and all the staff of Hengsai Biologicals to witness this important moment together. Har...

    View details
  • 2023 ASH |恒赛生物走向国际学术舞台，展示血液肿...

    2023 ASH | Hengsai Biotechnology to go to the international academic stage and present the latest research results of hematological oncology

    901

    Hengsai Bio USA - San Diego The 65th Annual Meeting of the American Society of Hematology (ASH) was grandly held in San Diego, USA on December 9-12, 2023. As the largest, most numerous and most influential annual meeting in the field of international hematology, this year's ASH Congress gathered 35,000 specialists and scholars from 109 countries and regions around the world to present their latest achievements, exchange ...

    View details
Expand more!

en_US
zh_CN en_US